Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13003281 | 0.88 | KCNH2 (0.39) | ACKR3KCNH2HRH3CYP3A4F10 | |
| SCHEMBL13060181 | 0.87 | ACKR3 (0.42) | ACKR3CCR2CYP3A4F10TBK1 | |
| SCHEMBL13003278 | 0.87 | KCNH2 (0.52) | KCNH2HRH3CYP3A4 | |
| SCHEMBL13391112 | 0.76 | ACKR3 (0.49) | ACKR3CYP3A4TBK1 | |
| SCHEMBL13060200 | 0.75 | ACKR3 (0.45) | ACKR3CCR2CYP3A4F10TBK1 | |
| SCHEMBL12533228 | 0.75 | ACKR3 (0.42) | ACKR3CYP3A4TBK1 | |
| SCHEMBL13003280 | 0.74 | ACKR3 (0.42) | ACKR3CYP3A4F10TBK1 | |
| SCHEMBL13060396 | 0.74 | ACKR3 (0.45) | ACKR3TBK1 | |
| SCHEMBL13391102 | 0.74 | ACKR3 (0.51) | ACKR3 | |
| SCHEMBL12533226 | 0.74 | ACKR3 (0.43) | ACKR3CYP3A4TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846946-B2 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING PLOUGH CORPORATION (US) | 2010-12-07 | — | — | US | disclosed |
| US-7635705-B2 | treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders; histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090286830-A1 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015807-A1 | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | HRH3, HRH4, CHRM2 | ACKR3 96/4885KCNH2 1142/4885HRH3 1/4885 |
| US-20090286830-A1 | HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | HRH3, HRH4, CHRM2 | ACKR3 96/4885KCNH2 1142/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.